QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor
News Jun 09, 2015
QMDx utilizes SCIENION's proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx's novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.
The companies' longstanding relationship was cemented with QMDx's purchase of SCIENION's sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterization from R&D to mass manufacture.
The instrument is the newest fixture in QMDx's chemistry facility at the University of Newcastle upon Tyne's Chemical Nanoscience Laboratories.
QMDx's Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx's R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."
"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
Portable Nose That Can Sniff Out Counterfeit LiquorNews
Watered-down or fake liquors can reap financial rewards for nefarious individuals, but the adulteration of liquor cheats consumers and can even lead to health hazards from added contaminants. Scientists now report a portable device with an advanced sensor array that can identify liquors and determine if they'd been altered, offering a strategy for liquor quality assurance.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018